That’s gotta hurt. FDA turns thumbs down on Spectrum’s 'breakthrough' pitch for cancer drug poziotinib and shares tumble
Everybody loves a breakthrough therapy drug designation from the FDA. But woe betide the public biotech company that comes away from the BTD quest empty …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
